To counter the argument that insufficient cell numbers were present at the time of SCH‐SC i.v. administration to allow unresponsiveness to develop, tolerance induction was therefore assessed at 1 (day 22 p.i.), 2 (day 29 p.i.), and 3 (day 36 p.i.)weeks after the final dose of CD52‐specific mAb (Fig. 5a). The gene discussed is CD52; the disease is spindle cell hemangioma.